一种新型宏化物EP395对急性中性恋呼吸道炎症的影响
Jennifer Ann Kricker1, Virginia Norris1, Clive Page2
1EpiEndo Pharmaceuticals Ehf., Bjargargata 1, 102, Reykjavik, Iceland.
Pulmonary pharmacology & therapeutics
|June 4, 2025
概括
EP395是一种新型的类化合物,在没有抗菌活性的临床前模型中有效降低了呼吸道炎症. 这表明EP395是慢性阻塞性肺病 (COPD) 的有前途的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 宏类抗生素通过免疫调节来减少呼吸道疾病的恶化,而不是通过抗菌作用.
- 长期使用类药物可能会导致抗菌素耐药性.
- EP395是一种新型化合物,旨在产生无抗菌活性的类效应.
研究的目的:
- 在中性友气道炎症模型中研究EP395的抗炎潜力.
- 为了评估EP395的疗效,与阿齐思罗米和罗米拉斯特相比.
- 为了在体外评估EP395对中性粒细胞功能的影响.
主要方法:
- EP395被口服给雄性BALB/c小鼠2周.
- 气道炎症是由脂聚糖 (LPS),烟草烟雾或呼吸道同胞病毒 (RSV) 诱导的.
- 测量了细胞因子水平和中性粒细胞透到支气管洗液 (BAL) 中. 在试验室中进行了中性粒细胞功能测试.
主要成果:
- 在所有三种模型中,EP395显著降低了炎症,细胞因子和中性粒细胞透.
- EP395的疗效与阿齐思罗米和罗米拉斯 (在LPS模型中) 的疗效相当.
- 实验室试验表明,EP395对中性粒细胞功能具有刺激和抑制作用.
结论:
- EP395在急性中性友性气道炎症的临床前模型中表现出显著的抗炎活性.
- EP395具有有益的药理特性,抗菌活性微不足道.
- EP395证明了临床开发作为一种潜在的COPD治疗方法.
关键词:
亚齐思罗密辛是一种亚齐思罗密辛.慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性肺炎.EP39595 这是一个很棒的节奏.表面上皮质 (epithelium) 是一个层次的表皮.免疫调节是一种免疫调节.炎症 炎症是一种炎症.麦克罗利德是什么 麦克罗利德是什么更多相关视频
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
11.0K
12:27The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 2, 2014
16.8K
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
505
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
505
01:17Drugs Used in Lower Respiratory Disorders: Overview
635
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
635
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
490
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
490